Josep M. Llibre

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson et al. · The Lancet · 2018 · 338 citations

Treatment And Prevention, Human Retrovirus, Antiviral Therapy +8

Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

Estebán Martínez, Juan A. Arnaiz, Daniel Podzamczer et al. · New England Journal of Medicine · 2003 · 293 citations · Full text

Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019

Dima Dandachi, Grant Geiger, Mary W. Montgomery et al. · Clinical Infectious Diseases · 2020 · 229 citations · Full text

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

Estebán Martínez, María Larrousse, Josep M. Llibre et al. · AIDS · 2010 · 191 citations

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng et al. · Clinical Infectious Diseases · 2022 · 152 citations · Full text